

Synthesis and Antimicrobial Activity of New *N*-[4-(4-Hydroxy-2-oxo-2*H*-chromen-3-yl)thiazol-2-yl]benzenesulfonamides

^aS. SUKDOLAK, ^aS. SOLUJIĆ, ^aN. MANOJLOVIĆ, and ^bLJ. KRSTIĆ

^aDepartment of Chemistry, Faculty of Science, University of Kragujevac, 34000 Kragujevac, Serbia & Montenegro
e-mail: duda@knez.uis.kg.ac.yu

^bICTM, Center of Chemistry, 11001 Belgrade, Serbia & Montenegro

Received 7 October 2003

New *N*-[4-(4-hydroxy-2-oxo-2*H*-chromen-3-yl)thiazol-2-yl]benzenesulfonamides were synthesized and their antimicrobial activity was tested in relation to some bacteria and fungi. Through the reaction of bromination with phenyltrimethylammonium tribromide, 3-acetyl-4-hydroxy-2*H*-chromen-2-one yields 3-bromoacetyl-4-hydroxy-2*H*-chromen-2-one which through reaction with thiourea gives 3-(2-aminothiazol-4-yl)-4-hydroxy-2*H*-chromen-2-one (*III*) in the form of a bromide salt. Compound *III* was the starting substrate in condensation reactions with corresponding arenesulfonyl chlorides yielding the required derivatives. Chemical structure of the obtained compounds was confirmed by elemental and structural analysis (IR, ¹H and ¹³C NMR). Also, the disk diffusion method was used to test the inhibitory activity of four of the new sulfonamides in relation to twelve microorganisms.

Derivatives of 2-aminothiazoles are important pharmacological compounds and precursors in syntheses of medicines [1] such as the antibiotic sulfathiazole and the antihelminthic thiabedazole. Moreover, recent research indicates that they are also inhibitors of enzymes such as kinurenine 3-hydroxylase [2]. On the other hand, derivatives of 4-hydroxy-2*H*-chromen-2-one are known as anticoagulants and antitumour compounds [3–5].

Aminothiazoles are obtained by means of the Hantzsch reaction [6–8]. Further functionalization of the starting aminothiazole derivatives involves formation of 3-bromoacetyl-4-hydroxy-2*H*-chromen-2-one (*II*) as a suitable synthon for reaction with thiourea to obtain 3-(2-aminothiazol-4-yl)-4-hydroxy-2*H*-chromen-2-one (*III*) (Scheme 1). In the next phase, reaction of *III* with corresponding arenesulfonyl chlorides yields *N*-[4-(4-hydroxy-2-oxo-2*H*-chromen-3-yl)thiazol-2-yl]-4*R*-benzenesulfonamide derivatives *IV*.


Compound *II* is useful in synthesis of substituted heterocyclic 2*H*-chromen-2-ones. However, its attainment through reaction with molecular bromine is hindered by pronounced sensitivity of the 2*H*-chromen-2-one ring to reactions of electrophilic substitution [9, 10]. Under the indicated conditions, for example, 4-acetyltropolone ring gave substitution products at the tropolone ring as a main product [11]. However, when 3-acetyl-4-hydroxy-2*H*-chromen-2-one (*I*), obtained by means of acetylation (by the method [12–14]) of 4-hydroxy-2*H*-chromen-2-one with acetic acid in the presence of phosphorous oxychloride,

is treated with phenyltrimethylammonium tribro-

midate [15, 16] in tetrahydrofuran, *II* is obtained in the form of yellow crystals (m.p. = 144–146 °C). Structure of this compound was determined on the basis of spectral data and elemental analysis. Three characteristic absorptions were observed in the IR spectrum: at 3185 cm⁻¹ (OH), 1725 cm⁻¹ (bromoacetyl, C=O), and 1685 cm⁻¹ (2*H*-chromen-2-one, C=O). The ¹H NMR spectrum shows a singlet peak at δ = 4.28 (2H) for CH₂, the signals at δ = 7.31–7.67 (4H) for aromatic ring protons, and a singlet peak at δ = 15.7 for OH group.

Compound *II* with thiourea in refluxing ethanol for a period of 30 min gives *III* in the form of a bromide salt. Spicular yellow crystals of compound *III* (m.p. = 255–257 °C) are obtained in a yield of 60 % by crystallization from a mixture of ethanol and 10 % sodium carbonate. The structure of compound *III* was determined on the basis of spectral data and elemental analysis. Three characteristic absorptions were observed in the IR spectrum: at 3381 cm⁻¹ (OH), 3122 cm⁻¹ (NH), and 1693 cm⁻¹ (C=O). In the ¹H NMR spectrum one isolated singlet was observed at δ = 7.21 for thiazole H-5'.

A mixture of *III* in the bromide form and the corresponding arenesulfonyl chloride [17] in pyridine was stirred overnight (12 h, r.t.). Following the completed reaction, the red reaction solution was neutralized with 1 M-HCl and filtered. A yellowish-orange crystalline dust (compounds *IVa*–*IVd*) was obtained as a result. The chemical structure of these compounds was determined on the basis of spectral data and elemental analysis.



i) Phosphorous oxychloride, acetic acid, reflux 30 min, ii) phenyltrimethylammonium tribromide, THF, 25 °C, 15 min, iii) (NH₂)₂CS, ethanol, reflux 30 min, iv) ArSO₂Cl, pyridine, 25 °C, 12 h.

Scheme 1

Table 1. The Inhibition Effect of Compounds *IVa*—*IVd* against Fungi and Bacteria

Microorganism	Inhibition by compounds/%			
	<i>IVa</i>	<i>IVb</i>	<i>IVc</i>	<i>IVd</i>
Fungus <i>Aspergillus niger</i>	45	36	42	44
Fungus <i>Doratomyces stemonitis</i>	39	31	35	36
Fungus <i>Trichoderma harzianum</i>	37	29	29	34
Fungus <i>Penicillium verrucosum</i>	48	43	43	46
Yeast <i>Candida albicans</i>	59	56	47	61
G ⁺ <i>Bacillus mycoides</i>	69	63	67	68
G ⁻ <i>Pseudomonas glicinea</i>	59	49	51	61
G ⁻ <i>Pseudomonas phaseolicola</i>	69	57	55	71
G ⁻ <i>Pseudomonas fluorescens</i>	75	70	64	77
G ⁻ <i>Escherichia coli</i>	76	75	65	79
G ⁻ <i>Pseudomonas aeruginosa</i>	49	46	49	56
G ⁺ <i>Staphylococcus aureus</i>	83	76	76	79

Table 1 presents in summary form results of disk diffusion testing [18] of the antimicrobial activity of compounds *IVa*—*IVd* in relation to some bacteria and fungi. The level of inhibition of some bacteria and fungi in the presence of *N*-[4-(4-hydroxy-2-oxo-2H-chromen-3-yl)thiazol-2-yl]-benzenesulfonamide derivatives (compounds *IVa*—*IVd*) was tested in the work. At the concentration of the tested compounds of 25 mg for bacteria and 100 mg for fungi, the microorganisms growth was reduced from 40 % to 80 %, and from 30 % to 60 %, respectively.

EXPERIMENTAL

The strains, *Penicillium verrucosum*, *Doratomyces stemonitis*, *Trichoderma harzianum*, *Aspergillus niger* (fungi) and *Bacillus mycoides*, *Pseudomonas glicinea*,

Pseudomonas phaseolicola, and *Pseudomonas fluorescens* (bacteria) are from the collection of microorganisms of the Faculty of Science, Department of Biology, University of Kragujevac.

Melting points were recorded on a Kofler hot-stage apparatus. Microanalysis of carbon, hydrogen, and nitrogen was carried out with an Erba 1106 microanalyzer. The IR spectra were run on a Perkin—Elmer grating spectrophotometers, Model 137 and Model 197. The NMR spectra were recorded on a Varian FT 80 A and 200" Gemini spectrometers, in CDCl₃ and DMSO-*d*₆, using TMS as the internal standard. Chemical shifts are given in δ; abbreviations: s – singlet, d – doublet, t – triplet, q – quartet, m – multiplet, and br – broadened. Abbreviations used: PhTAPBr₃ – phenyltrimethylammonium tribromide, DMSO – dimethyl sulfoxide-*d*₆.

3-Acetyl-4-hydroxy-2H-chromen-2-one (I)

To a solution of 4-hydroxychromen-2-one (3 g; 18.6 mmol) in acetic acid (16 cm³) phosphorous oxychloride (5.6 cm³) was added. The mixture was heated at reflux for 30 min. After cooling, the precipitate was collected and recrystallized from ethanol to give white needles in a yield of 2.7 g (90 %); m.p. = 134–136 °C. IR spectrum (KBr), $\tilde{\nu}_{\max}/\text{cm}^{-1}$: 3185, 2950, 1705, 1700, 1610, 1560, 1460, 1310, 1130, 950, 840, 820, 770. ¹H NMR spectrum (200 MHz, CDCl₃), δ : 2.43 (s, 3H, CH₃), 7.35 (ddd, 1H, C-6—H, ³J_{6,5} = 7.8 Hz, ⁴J_{6,8} = 1.2 Hz), ³J_{6,7} = 7.4 Hz), 7.42 (dd, 1H, C-8—H, ³J_{7,8} = 8.35 Hz, ⁴J_{6,8} = 1.2 Hz, 7.42 (ddd, 1H, C-7—H, ³J_{7,8} = 8.35 Hz, ³J_{7,6} = 7.4 Hz, ⁴J_{7,5} = 1.6 Hz), 7.69 (dd, 1H, C-5—H, ³J_{5,6} = 7.8 Hz, ⁴J_{5,7} = 1.6 Hz), 15.7 (OH). ¹³C NMR spectrum (50 MHz, CDCl₃), δ : 28.33 (CH₃), 160.10 (CO), 177.32 (C-4), 116.91 (C-8), 159.65 (C-2), 154.10 (C-9), 136.85 (C-7), 116.09 (C-5), 124.82 (C-6), 114.41 (C-10), 101.91 (C-3). Mass spectrum, m/z ($I_r/\%$): 204 (100), 189 (74), 161 (43), 120 (17), 119 (31), 92 (56), 78 (33), 43 (28). For C₁₁H₈O₄ (M_r = 204.0423) w_i (calc.): 64.71 % C, 3.95 % H; w_i (found): 64.92 % C, 3.68 % H.

3-Bromoacetyl-4-hydroxy-2H-chromen-2-one (II)

To a solution of I (2.0 g; 9.8 mmol) in tetrahydrofuran (b.p. = 60 °C, 40 cm³) phenyltrimethylammonium tribromide (3.68 g; 9.8 mmol) was added in a period of 15 min, at room temperature (25 °C). A precipitate was deposited from the solution, and the colour of the solution changed into pale yellow. After stirring for 20 min and standing for 30 min, cold water (100 cm³) was added to the reaction mixture. The precipitate was collected, washed with water and recrystallized from ethanol to afford light yellow needles in a yield of 2.51 g (90 %); m.p. = 144–146 °C. IR spectrum (KBr), $\tilde{\nu}_{\max}/\text{cm}^{-1}$: 3185, 1725, 1685, 1560, 1437, 1200, 1032, 945, 842, 822, 771. ¹H NMR spectrum (200 MHz, CDCl₃), δ : 4.28 (s, 2H, CH₂), 7.31 (ddd, 1H, C-6—H, ³J_{6,5} = 7.38 Hz, ⁴J_{6,8} = 1.16 Hz, ³J_{6,7} = 7.32 Hz), 7.39 (dd, 1H, C-8—H, ³J_{7,8} = 8.35 Hz, ⁴J_{6,8} = 1.16 Hz), 7.42 (ddd, H, C-7—H), ³J_{7,8} = 8.35 Hz, ³J_{7,6} = 7.37 Hz, ⁴J_{7,5} = 1.63 Hz), 7.69 (dd, 1H, C-5—H, ³J_{5,6} = 7.89 Hz, ⁴J_{5,7} = 1.63 Hz), 15.7 (OH). ¹³C NMR spectrum (50 MHz, CDCl₃), δ : 33.41 (CH₂), 183.50 (CO), 185.32 (C-4), 115.91 (C-8), 158.65 (C-2), 153.00 (C-9), 134.85 (C-7), 125.09 (C-5), 124.82 (C-6), 119.41 (C-10), 100.91 (C-3). For C₁₁H₇O₄Br (M_r = 281.9528) w_i (calc.): 46.67 % C; 2.49 % H; w_i (found): 46.92 % C, 2.38 % H.

3-(2-Ammoniothiazol-4-yl)-4-hydroxy-2H-chromen-2-one Bromide (III)

To a solution of II (1 g; 3.5 mmol) in absolute

ethanol (60 cm³) thiourea (0.270 g; 3.5 mmol) was added. The mixture was heated at reflux for 30 min. After cooling, the precipitate was collected and recrystallized from ethanol—10 % sodium hydroxide to give yellow needles in a yield of 0.71 g (60 %); m.p. = 255–257 °C. IR spectrum (KBr), $\tilde{\nu}_{\max}/\text{cm}^{-1}$: 3433, 3381, 3241, 3122, 1698, 1609, 1524, 1405, 1328, 1294, 1165, 1072, 950. ¹H NMR spectrum (200 MHz, CDCl₃), δ : 7.29–7.37 (m, 2H, C-6—H, C-8—H, ⁴J_{6,8} = 1.16 Hz, ³J_{6,5} = 7.90 Hz, ³J_{6,7} = 7.35 Hz, ³J_{8,7} = 8.35 Hz), 7.21 (s, 1H, C'-5—H), 7.44 (ddd, 1H, C-7—H, ³J_{6,7} = 7.35 Hz, ⁴J_{7,5} = 1.63 Hz, ³J_{8,7} = 8.35 Hz), 8.58 (bs, 1H, NH₂), 15.87 (s, 1H, OH). ¹³C NMR (50 MHz, DMSO-*d*₆), δ : 165.42 (C'-2), 140.67 (C'-4), 108.56 (C'-5), 154.28 (C-2), 93.86 (C-3), 163.09 (C-4), 123.76 (C-5), 124.06 (C-6), 132.11 (C-7), 116.34 (C-8), 120.23 (C-10), 152.05 (C-9). For C₁₂H₉BrN₂O₃S (M_r = 260.2685, recrystallized from ethanol—10 % sodium carbonate) w_i (calc.): 55.37 % C, 3.10 % H, 10.76 % N; w_i (found): 55.12 % C, 2.98 % H, 10.38 % N.

N-[4-(4-Hydroxy-2-oxo-2H-chromen-3-yl)-thiazol-2-yl]-4-R-benzenesulfonamides IVa—IVd

A mixture of III (5.1 g; 15 mmol) and arenesulfonyl chloride (17 mmol) in pyridine (5 cm³) was stirred overnight (12 h) at room temperature (25 °C). The red solution was poured into 1 M-HCl (50 cm³). The yellowish precipitate was collected, redissolved in a mixture of ethanol (20 cm³) and 2 M-NaOH (20 cm³) and treated with activated charcoal – Norite. Filtration and neutralizing of the filtrate with concentrated HCl yielded the product as a yellow-orange powder, which was recrystallized from EtOH—water mixture.

N-[4-(4-Hydroxy-2-oxo-2H-chromen-3-yl)thiazol-2-yl]-4-methylbenzenesulfonamide (IVa), 2.6 g (43 %) of a yellow-orange powder from 30 % EtOH; m.p. > 260 °C. IR spectrum (KBr), $\tilde{\nu}_{\max}/\text{cm}^{-1}$: 3381, 3340, 3165, 3220, 3080, 3060, 1360, 1345, 1170, 1689, 1560, 1490, 1150, 1070, 840. ¹H NMR spectrum (200 MHz, CDCl₃), δ : 2.32 (s, 3H, CH₃), 7.41–7.71 (m, 4H, C-5—H, C-6—H, C-7—H, C-8—H), 8.22 (s, 1H, C-5'-H), 7.32 (d, 2H, C-2—H, C-6—H, ³J = 8.53 Hz, H_{arom}), 7.61 (d, 2H, C-3—H, C-5—H, ³J = 8.53 Hz, H_{arom}), 8.95 (bs, 1H, NH), 10.90 (s, 1H, OH). ¹³C NMR (50 MHz, DMSO-*d*₆), δ : 154.28 (C-2), 90.54 (C-3), 163.09 (C-4), 125.79 (C-5), 125.1 (C-6), 129.92 (C-7), 118.95 (C-8), 151.71 (C-9), 127.6 (C-10), 165.4 (C-2'), 107.76 (C-5'), 141.47 (C-4'), 21.50 (CH₃), 144.17 (Ar, C-1), 130.57 (Ar, C-2), 126.99 (Ar, C-3), 138.78 (Ar, C-4), 126.99 (Ar, C-5), 130.57 (Ar, C-6). For C₁₉H₁₄N₂O₅S₂ w_i (calc.): 39.87 % C, 3.01 % H, 9.33 % N; w_i (found): 40.12 % C, 2.92 % H, 9.28 % N.

4-Chloro-*N*-[4-(4-hydroxy-2-oxo-2H-chromen-3-yl)-thiazol-2-yl]benzenesulfonamide (IVb), 0.57 g (41 %) of an orange powder from 50 % EtOH, m.p. ≈ 259–260 °C. IR spectrum (KBr), $\tilde{\nu}_{\max}/\text{cm}^{-1}$: 3361, 3355,

3145, 3215, 1350, 1325, 1695, 815 cm^{-1} . ^1H NMR spectrum (200 MHz, CDCl_3), δ : 7.29–7.71 (m, 4H, C-5—H, C-6—H, C-7—H, C-8—H), 8.31 (s, 1H, C-5'—H), 7.44 (d, 2H, C-3—H, C-5—H, $^3J = 8.35$ Hz, H_{arom}), 7.79 (d, 2H, C-2—H, C-6—H, $^3J = 8.35$ Hz, H_{arom}), 8.90 (bs, 1H, NH), 11.5 (s, 1H, OH). For $\text{C}_{18}\text{H}_{11}\text{ClN}_2\text{O}_5\text{S}_2$ w_i (calc.): 49.71 % C, 2.55 % H, 6.44 % N; w_i (found): 49.34 % C, 2.42 % H, 6.28 % N.

N-[4-(4-Hydroxy-2-oxo-2H-chromen-3-yl)thiazol-2-yl]-4-methoxybenzenesulfonamide (IVc), 0.31 g (37 %) of a yellow-orange powder from 30 % EtOH, m.p. = 242–244 °C. IR spectrum (KBr), $\tilde{\nu}_{\text{max}}/\text{cm}^{-1}$: 3351, 3137, 3212, 1346, 1335, 1690, 1205, 1055. ^1H NMR spectrum (200 MHz, $\text{DMSO}-d_6$), δ : 7.3–7.7 (m, 4H, C-5—H, C-6—H, C-7—H, C-8—H), 7.48 (d, 2H, C-3—H, C-5—H, $^3J = 9.1$ Hz, H_{arom}), 7.98 (d, 2H, C-2—H, C-6—H, $^3J = 9.1$ Hz, H_{arom}), 8.28 (s, H, C-5'—H), 8.65 (bs, 1H, NH), 10.89 (s, 1H, OH). For $\text{C}_{19}\text{H}_{14}\text{N}_2\text{O}_6\text{S}_2$ w_i (calc.): 53.01 % C, 3.28 % H, 6.51 % N; w_i (found): 52.68 % C, 3.34 % H, 6.39 % N.

4-Amino-*N*-[4-(4-hydroxy-2-oxo-2H-chromen-3-yl)-

thiazol-2-yl]benzenesulfonamide (IVd), 0.46 g (55 %) of an orange powder from 50 % EtOH, m.p. > 260 °C. IR spectrum (KBr), $\tilde{\nu}_{\text{max}}/\text{cm}^{-1}$: 3451, 3345, 3130, 2950, 1678, 1344, 1339. ^1H NMR spectrum (200 MHz, $\text{DMSO}-d_6$), δ : 7.35–7.75 (m, 4H, C-5—H, C-6—H, C-7—H, C-8—H), 6.78 (d, 2H, C-3—H, C-5—H, $^3J = 9.1$ Hz, H_{arom}), 7.8 (d, 2H, C-2—H, C-6—H, $^3J = 9.1$ Hz, H_{arom}), 8.19 (s, 1H, C-5'—H), 7.05 (bs, 2H, NH_2), 8.75 (bs, 1H, NH), 10.85 (s, 1H, OH). For $\text{C}_{18}\text{H}_{13}\text{N}_3\text{O}_5\text{S}_2$ w_i (calc.): 52.04 % C, 3.15 % H, 10.11 % N; w_i (found): 51.94 % C, 3.08 % H, 9.99 % N.

Antimicrobial Assays

The disk diffusion method was used for screening of antifungal (100 mg/disk) and antibacterial activity (25 mg/disk) of the derivatives. The plates were inoculated with the desired microorganisms before placing compound-impregnated paper disks on them. Nystatin and penicillin (for antifungal testing) and gentamycin (for antibacterial testing) were used as positive controls.

Staphylococcus aureus, *Escherichia coli*, and *Pseudomonas aeruginosa* were grown on ANTIBIOTIC MEDIUM 1 (Difco Laboratories). *Penicillium verrucosum*, *Doratomyces stemonitis*, *Trichoderma harzia-*

num, *Aspergillus niger*, *Candida albicans* (fungi) and *Bacillus mycoides*, *Pseudomonas glycinia*, *Pseudomonas phaseolicola*, *Pseudomonas fluorescens* (bacteria) were grown on TRIPTON SOYA AGAR (Torklak – Beograd). Disks ANTIBIOTICA TEST BLATTCHEN (Dasel, Germany) were immersed in ethanol solution of compounds IVa–IVd, then put on the antibiotic medium sown with microorganisms and kept at 37 °C, except for *Candida albicans* which was kept at 25 °C. After 18 h the activities were determined on a FISHER-LILLY ANTIBIOTIC ZONE READER, by measuring the diameter of biological activity zone round the disks.

REFERENCES

1. Sammes, P. G., *Sulfonamides and Sulfones, Comprehensive Medicinal Chemistry*, Vol. 2, p. 255–270. Pergamon Press, Oxford, 1990.
2. Rover, S., Cesura, M. A., Huguenin, P., and Szente, A., *J. Med. Chem.* 40, 4378 (1997).
3. Wattenberg, L. W., Low, L. K. T., and Fladmoe, A. V., *Cancer Res.* 39, 1651 (1979).
4. Willette, R. E. and Soine, T. O., *J. Pharm. Sci.* 51, 149 (1961).
5. Dean, F. M., *Naturally Occurring Oxygen Ring Compounds*. Pp. 176–220. Butterworth, London, 1963.
6. Qian, Chang-Yi, Jin, Zhong-Tian, and Yin, Bing-Zhu, *J. Heterocycl. Chem.* 26, 601 (1989).
7. Wiley, R. H., England, D. C., and Behr, L. C., *Org. React.* 6, 367 (1951).
8. Elderfield, R. C., *The Chemistry of Heterocyclic Compounds*, Vol. 5. Wiley, New York, 1956.
9. Nozoe, T., *Non-Benzenoid Aromatic Compounds*. (Ginsburg, D., Editor.) Pp. 339–463. Interscience Publishers, New York, 1959.
10. Lloyd, D., *Non-Benzenoid Conjugated Carbocyclic Compounds*. Pp. 102–125. Elsevier, Amsterdam, 1984.
11. Takase, K., Kasai, K., Shimizu, K., and Nozoe, T., *Bull. Chem. Soc. Jpn.* 44, 2466 (1971).
12. Jutz, C., *Adv. Org. Chem.* 9, 225 (1976).
13. De Maheas, Marie-Robert, *Bull. Soc. Chim. Fr.* 29, 1989 (1962).
14. Meth-Cohn, O. and Stanforth, S. P., *Comp. Org. Syn.* 2, 777 (1991).
15. Fieser, M. and Fieser, L. F., *Reagents for Organic Synthesis*, Vol. 4, pp. 56–57. Mir, Moscow, 1971.
16. Viswewariah, S., *Synthesis* 1982, 309.
17. *Vogel's Textbook of Practical Organic Chemistry*. Pp. 651–653. Longman, London, 1986.
18. *Pharmacopoea Jugoslavica edito quatra*, PH. JUG. IV. P. 156–158. Federal Bureau for Health Protection, Belgrade, 1984.